Search
All Clinical Trials
A listing of 23130 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
25 - 36 of 23130
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Recruiting
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +344 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Recruiting
BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications. We evaluated the efficacy of an alternative serotype, type F. Under other protocols, we continue to study the physiology of movement disorders and BTX response.
The application of BTX therapy to movement disorders requires an understanding of BTX preparation and handling. The treatment mus... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Movement Disorders
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Recruiting
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try t... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer
Surgery as a Treatment for Medically Intractable Epilepsy
Recruiting
Background:
- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery. The tests and surgery performed as part of this treatment are not experimental, but researchers are interested in using the data collected as part of routine standard epilepsy... Read More
Gender:
ALL
Ages:
Between 8 years and 99 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Reproductive Axis Maturation in the Early Post-Menarchal Years
Recruiting
Background:
Most adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.
Objective:
To learn how long it takes girls to develop regular menstrual cycles after their firs... Read More
Gender:
FEMALE
Ages:
Between 8 years and 34 years
Trial Updated:
06/25/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Reproductive Physiological Processes, Pediatrics, Adolescent Health, Adolescent Development
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Recruiting
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +110 locations
Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Recruiting
Background:
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.
Objective:
To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, Lymphoma, Non-Hodgkin, B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, B-precursor ALL, B-All
Self-Management Program for AIS D SCI
Recruiting
About 25-51% of adults with acquired spinal cord injury (SCI) have "AIS D" SCI, the lowest severity grade of neurologic injury. Veterans with AIS D SCI generally have better outcomes in mobility, community integration, and employment. However, counterintuitively, they are also at higher risk of poor subjective well-being (SWB) and related psychosocial outcomes. Preliminary evidence suggests that poorer SWB in this group is associated with distinctive, modifiable factors such as less intensity of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/25/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Psychological Well-Being, Spinal Cord Injuries
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Recruiting
Primary Objective:
To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity.
Secondary Objectives:
1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS.
2. To evaluate the safety and tolerability of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona +247 locations
Conditions: Sjogren's Syndrome
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Recruiting
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Associated Retina Consultants, Ltd., Phoenix, Arizona +81 locations
Conditions: Diabetic Retinopathy
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Recruiting
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Apogee Clinical Research, Huntsville, Alabama +145 locations
Conditions: Kidney Disease, Chronic
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Recruiting
Background:
About 1.5 million adults in the US enter alcohol or substance use treatment programs each year. Unfortunately, more than half of patients do not finish their program. For those who start treatment, about 70% return to substance use within weeks or months after starting treatment. To discover why patients drop out of treatment and return to substance use - and what can be done about it - researchers need to learn more about people who use drugs and alcohol.
Objective:
To create a d... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/25/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Alcoholism, Substance-Related Disorders
25 - 36 of 23130